Domatinostat
Small moleculeexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01344707)
Timeline
Indications
Mechanism of action
- LSD1/CoREST complexINHIBITOR
LSD1/CoREST complex inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cc(-c2ccc(S(=O)(=O)n3ccc(/C=C/C(=O)Nc4ccccc4N)c3)cc2)cn1- Mol. weight
- 447.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4283683 ↗
Also known as
- 4sc-202
- 4sc-202
- 4sc-202
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04874831 | Phase 2 | Nov 1, 2021 | 4SC AG, Merck KGaA |
| NCT04871594 | Phase 1 | Aug 23, 2021 | 4SC AG, Netherlands Cancer Institute |
| NCT04393753 | Phase 2 | Jul 31, 2020 | 4SC AG |
| NCT04133948 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2019 | 4SC AG, Netherlands Cancer Institute |
| NCT03812796 | Phase 2 | Jan 11, 2019 | 4SC AG, Merck KGaA, Royal Marsden Hospital NHS Trust |
| NCT03278665 | Phase 1/Phase 2 (Phase 2) | Sep 25, 2017 | 4SC AG |
| NCT01344707 | Phase 1 | Mar 1, 2011 | 4SC AG, University of Cologne |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| 4SC AG | For profit | 7 | 4 | 2 | 2011 |
| Merck KGaA | For profit | 2 | 0 | 1 | 2019 |
| Netherlands Cancer Institute | Academic/Hospital | 2 | 2 | 2 | 2019 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Cologne | Academic/Hospital | 1 | 0 | 1 | 2011 |
5 organizations
Page 1 / 1